---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-016929"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:40:17.989069+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma provides corporate presentation ahead of March 27 PDUFA for CARDAMYST

## Summary
- NDA for CARDAMYST (etripamil) nasal spray remains under FDA review with PDUFA date of March 27, 2025.
- Presentation outlines potential commercial launch strategy, but product is not yet approved.
- Company actively preparing for launch pending FDA decision.
- Presentation used at investor meetings; available on company website.

## SEC filing metadata
- accession: 0001104659-25-016929
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465925016929/0001104659-25-016929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465925016929/tm257508d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-016929
- JSON: https://secwatch.observer/filing/0001104659-25-016929.json
- Plain text: https://secwatch.observer/filing/0001104659-25-016929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.